Sourcing Guide

Cagrilintide in Canada: The Long-Acting Amylin Analogue

The compound that made amylin the incretin field's second act, with published phase 2 data and no approval

July 9, 2026·Compiled by Eppix Labs

Amylin is the pancreatic hormone co-secreted with insulin, and for two decades its therapeutic potential was limited by the fact that native human amylin aggregates into amyloid fibrils. Cagrilintide is the analogue that solved that problem well enough to reach late-stage development, and its arrival is the reason amylin biology is now the most active area in metabolic research after the incretins.

This guide covers the molecule, the published trials, and the verification checks. Cagrilintide is supplied for laboratory research use only and is not approved anywhere.

Chemical Identity

Name: Cagrilintide (AM833)
Also known as: Cagrilintide, AM833, NNC0174-0833
Molecular formula: C₁₉₄H₃₀₆N₅₆O₅₉
Molecular weight: 4326.9 g/mol
CAS number: 1802884-83-2
Salt forms: Acetate (research supply)

What cagrilintide is

Cagrilintide is a synthetic, lipidated, long-acting analogue of human amylin, engineered for once-weekly administration. Its backbone borrows from both human amylin and salmon calcitonin, which is the standard route to an amylin analogue that resists aggregation, and it carries a C20 fatty diacid for albumin binding.

Amylin signals through receptor complexes formed between the calcitonin receptor and receptor-activity-modifying proteins (RAMP1, RAMP2, RAMP3). Cagrilintide engages those complexes with a broader profile than a strictly selective agonist would, which is the pharmacological difference between it and newer selective compounds such as eloralintide.[4]

General Image — Cagrilintide lyophilized research material as supplied by Eppix Labs. Labelled and measured content are stated on the certificate below.

Sequence and structure

A 32-residue lipidated peptide near 4327 Da with a disulfide bridge near the N-terminus. The disulfide is a genuine quality attribute rather than a detail: incorrectly folded or reduced material has the same amino-acid composition and a mass differing by 2 Da, which is within the noise of a careless mass read and entirely resolvable by a competent one.

Amino Acid Sequence diagram — Amino-acid sequence of cagrilintide.

Chemical Structure diagram — Chemical structure of cagrilintide.

What the published trials reported

Three published randomised trials define the public record:

·Phase 2, monotherapy. Lau et al., Lancet 2021: a 26-week randomised, double-blind, placebo-controlled dose-finding trial in adults with overweight or obesity, reporting dose-dependent weight reduction against placebo and against liraglutide 3.0 mg.[1]
·Phase 1b, combination. Enebo et al., Lancet 2021: concomitant administration of cagrilintide with semaglutide 2.4 mg, the trial that established the combination now known as CagriSema.[2]
·Phase 2, type 2 diabetes. Frias et al., Lancet 2023: co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes, against semaglutide alone.[3]

The limit of the evidence

Cagrilintide has no marketing authorization in any jurisdiction, alone or in combination. Its published record is phase 1b and phase 2, generated with GMP material at defined doses under clinical supervision. Health Canada has authorized nothing containing it.

A great deal of commentary treats the combination results as if they were cagrilintide results. They are not: in the combination trials the amylin analogue is one of two active components, and separating its contribution requires the monotherapy arm.

Verifying a cagrilintide lot

Identity by mass spectrometry against the expected mass near 4327 Da, HPLC purity, and measured content against the labelled amount. For an aggregation-prone class, one additional practical check: material that has partially aggregated may not fully redissolve on reconstitution, and a vial that leaves visible particulate after the recommended reconstitution volume and time is telling you something a certificate issued at manufacture cannot.

Every Eppix cagrilintide lot is tested by Janoshik Analytical, published before sale and verifiable on the laboratory's own database.

Certificate of analysis for Buy Cagrilintide Canada | Amylin Analog 5mg, batch CAG-CA-26A-01 — Published certificates for the current cagrilintide lots, by strength, read live from the batch record.

Sourcing in Canada

Domestic fulfilment is by Canada Post Xpresspost, typically one to two days nationwide, free over $200, with an Interac e-Transfer discount and mix-and-match pricing at 5 and 10 vials.

The newer selective amylin agonist is covered at buy eloralintide in Canada, and the semaglutide guide at buy semaglutide in Canada.

Eppix Labs catalogue

Buy Cagrilintide Canada | Amylin Analog

5mg · 10mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $90.00 CADOut of stock

Frequently Asked

No. As of August 2026 it has no marketing authorization in any jurisdiction, alone or in the CagriSema combination. Its published record is phase 1b and phase 2.

Amylin is a 37-residue hormone co-secreted with insulin from pancreatic beta cells, signaling satiety and slowing gastric emptying. It is pharmacologically interesting because it acts through a pathway distinct from the incretins, which is why amylin and GLP-1 agents are studied in combination.

Human amylin aggregates into amyloid fibrils, which makes it unsuitable as a formulated agent. Analogues in this class borrow structural features from salmon calcitonin to resist aggregation.

Both act on amylin receptor complexes. Cagrilintide is a long-acting analogue with a broader receptor profile and a later-stage development programme; eloralintide is designed for amylin-receptor selectivity and is earlier in development.

It may be sold and held as a laboratory research material. It is not authorized by Health Canada for human or veterinary use. This is not legal advice.

Lyophilized: cool, dry, dark, at -20 °C for long-term storage. Reconstituted: refrigerated, handled gently, used within the window your protocol defines. Aggregation-prone peptides do not benefit from vigorous agitation.

References

Lau, D.C.W. et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 398(10317):2160-2172. PMID 34798060
Enebo, L.B. et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 397(10286):1736-1748. PMID 33894838
Frias, J.P. et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 402(10403):720-730. PMID 37364590
Hay, D.L. et al. (2015). Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev 67(3):564-600. PMID 26071095

Buy Eloralintide Canada | Amylin Agonist

From $150.00 CAD · Janoshik-verified COA

Buy Cagrilintide Canada | Amylin Analog

From $90.00 CAD · Janoshik-verified COA

Research Use Only

This article summarizes published preclinical research literature. Compounds referenced are supplied by Eppix Labs strictly as research materials for laboratory investigation within Canada. They are not approved by Health Canada for human or veterinary use, and nothing on this page should be interpreted as medical advice or guidance on human or animal administration.